(Q37204970)

18 August 2017

1 reference

title

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications (English)

1 reference

18 August 2017

2

Fortunato Ciardiello

1 reference

18 August 2017

Giampaolo Tortora

1

1 reference

PubMed ID

18594498

18 August 2017

Giampietro Gasparini

series ordinal

3

1 reference

18 August 2017

1 July 2008

1 reference

Nature Clinical Practice Oncology

18 August 2017

1 reference

18 August 2017

5

1 reference

18 August 2017

9

1 reference

18 August 2017

521-530

1 reference

Tumor angiogenesis: therapeutic implications

18 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Transplacental carcinogenesis by stilbestrol

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Role of hypoxia-inducible factor-1alpha as a cancer therapy target

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Epidermal growth factor receptor in tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Angiogenic inhibitors: a new therapeutic strategy in oncology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

A model system for tumor angiogenesis: involvement of transforming growth factor-alpha in tube formation of human microvascular endothelial cells induced by esophageal cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Cyclooxygenase-2: a therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypox

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Molecular determinants of cetuximab efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1161

7 January 2021

Identifiers

DOI

10.1038/NCPONC1161

1 reference

18 August 2017

1 reference

PubMed ID

18594498